Please login to the form below

Not currently logged in
Email:
Password:

liver transplant

This page shows the latest liver transplant news and features for those working in and with pharma, biotech and healthcare.

Promethera’s liver failure stem cell therapy clears first hurdle

Promethera’s liver failure stem cell therapy clears first hurdle

Technique could be alternative to transplant. A stem cell-based therapy for a serious form of liver failure has been shown to be safe and improve liver function biomarkers in a ... At the moment, the only treatment for patients whose liver disease has

Latest news

  • Genfit launches $135m IPO to back NASH plans Genfit launches $135m IPO to back NASH plans

    fund a phase 4 post-marketing study in patients with the liver disease. ... It causes fatty build-up and fibrosis in the liver, in serious cases leading to cirrhosis and the need for a liver transplant.

  • Liver specialist Genfit files $120m IPO on Nasdaq Liver specialist Genfit files $120m IPO on Nasdaq

    Funds will go towards NASH candidate, a companion diagnostic and a liver disease drug. ... for a liver transplant.

  • Intercept NASH drug closes in on FDA approval Intercept NASH drug closes in on FDA approval

    NASH causes fatty build-up and fibrosis in the liver, which in serious cases can lead to cirrhosis and the need for a liver transplant. ... Intercept’s trial enrolled mainly patients with stage 2 and 3 liver fibrosis, with a small group of patient with

  • Gilead lead NASH drug flunks phase 3 test Gilead lead NASH drug flunks phase 3 test

    It causes fatty build-up and fibrosis in the liver, in serious cases leading to cirrhosis and the need for a liver transplant. ... In phase 2 testing, VK2809 was shown to significantly reduce fat in the liver – another key pathology in NASH – and

  • Merck’s backing of NGM Bio yields NASH drug deal Merck’s backing of NGM Bio yields NASH drug deal

    It causes fatty build-up and fibrosis in the liver, sometimes leading to cirrhosis and the need for a liver transplant, and so far has no approved treatments with some analysts ... levels of fat in the liver and improve metabolic measures such as blood

More from news
Approximately 3 fully matching, plus 39 partially matching documents found.

Latest Intelligence

  • 2016: The year when deal-makers took stock? 2016: The year when deal-makers took stock?

    NASH and biosimilars. One therapeutic indication that could be seen to be gaining much attention was NASH, which is the fastest growing cause of liver cancer and liver transplant in the

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics